The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
A RNA antagonist of hypoxia-inducible factor-1α, EZN-2968, inhibits tumor cell growth
Open accessAbstract
Hypoxia-inducible factor-1 (HIF-1) is a transcription factor that plays a critical role in angiogenesis, survival, metastasis, drug resistance, and glucose metabolism. Elevated expression of the α-subunit of HIF-1 (HIF-1α), which occurs in response to hypoxia or activation of growth factor pathways, is associated with poor prognosis in many types of cancer. Therefore, down-regulation of HIF-1α protein by RNA antagonists may control cancer growth. EZN-2968 is a RNA antagonist composed of third-generation oligonucleotide, locked nucleic acid, technology that specifically binds and inhibits the expression of HIF-1α mRNA. In vitro, in human prostate (15PC3, PC3, and DU145) and glioblastoma (U373) cells, EZN-2968 induced a potent, selective, and durable antagonism of HIF-1 mRNA and protein expression (IC50, 1-5 nmol/L) under normoxic and hypoxic conditions associated with inhibition of tumor cell growth. Additionally, down-regulation of HIF-1α protein by EZN-2968 led to reduction of its transcriptional targets and of human umbilical vein endothelial cell tube formation. In vivo, administration of EZN-2968 to normal mice led to specific, dose-dependent, and highly potent down-regulation of endogenous HIF-1α and vascular endothelial growth factor in the liver. The effect can last for days after administration of single dose of EZN-2968 and is associated with long residence time of locked nucleic acid in certain tissues. In efficacy studies, tumor reduction was found in nude mice implanted with DU145 cells treated with EZN-2968. Ongoing phase I studies of EZN-2968 in patients with advanced malignancies will determine optimal dose and schedule for the phase II program. [Mol Cancer Ther 2008;7(11):3598–608]
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IC50 values for the HIF-2α isoform, with which EZN-2968 has a 3-base-pair mismatch, were 5 times higher in all cell lines tested compared to IC50 values for HIF-1α, supporting the relative selectivity of EZN-2968 for HIF-1α [11].”
From Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors (2014) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because preclinical biodistribution studies of EZN-2968 documented prolonged and preferential retention in the liver [11]”
From Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors (2014) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It was reported that inhibition of HIF-1α by EZN-2698 attenuates HIF-1α protein level and tumor progression in various in vitro (human prostate and glioblastoma cell lines) and in vivo studies52.”
From HIF-1α pathway: role, regulation and intervention for cancer therapy (2015) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“EZN-2698 (1) is an anti-sense oligonucleotide, an RNA antagonist which specifically binds and inhibits the expression of HIF-1α mRNA as well as HIF-1α target genes.”
From HIF-1α pathway: role, regulation and intervention for cancer therapy (2015) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The in vivo effect of EZN-2968 has also been tested in a subcutaneous prostate cancer cell line xenograft model and, although treatment did not result in a significant reduction in tumor burden, pre-treatment of cells with EZN-2968 prior to injection resulted in a significant reduction in tumor size.”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Greenberger et al., 2008
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In vitro, it potently suppresses HIF-1α protein accumulation with IC50 values in the low-nanomolar range (1–5 nM) under both normoxic and hypoxic conditions.”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [281]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“EZN-2968 binds specifically to HIF1A mRNA, promoting transcript degradation and inhibiting translation [280,281].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [281]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In preclinical studies, EZN-2968 effectively attenuated transcription of HIF-1 target genes and inhibited hypoxia-driven angiogenesis in multiple cancer models, including prostate cancer, glioblastoma, and DU145 xenografts [281].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [281]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“EZN-2968 is an LNA antisense oligodeoxynucleotide that has been demonstrated to hybridize with HIF-1α mRNA and block HIF-1α protein expression in preclinical models [11].”
From Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors (2014) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Tumor growth inhibition was observed in xenograft models [11].”
From Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors (2014) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“EZN-2968 has a three base pair mismatch with the HIF-2α sequence and, as a consequence, only downregulates HIF-2α mRNA by 20% at 25 nM.”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Greenberger et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“EZN-2968 binding leads to HIF-1α mRNA downregulation in a dose-dependent manner and results in near complete inhibition at 5 nM concentrations (Greenberger et al., 2008).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Greenberger et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“EZN-2968 treatment of tumor cells in vitro downregulated HIF-1α protein levels during hypoxia and reduced the growth rate.”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Greenberger et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“Due to a three-nucleotide mismatch, its activity toward EPAS1 (HIF-2α) mRNA is minimal [281].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [281]
The cited source says what the claim attributes to it.
In the citing paper
“EZN-2968 is built on locked nucleic acid (LNA) chemistry, in which a methylene bridge between the 2′-oxygen and 4′-carbon of the ribose ring locks the sugar into a rigid conformation. This structural feature enhances base-pairing affinity, nuclease resistance, and in vivo stability relative to conventional oligonucleotides [[279], [280], [281]].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [281]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653
Mitochondrial reactive oxygen species trigger hypoxia-induced transcription
Chandel, N. S., Maltepe, E., Goldwasser, E., Mathieu, C. E., Simon, M. C., & Schumacker, P. T. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.11715 · Cited by 1,926
Hypoxia signalling in cancer and approaches to enforce tumour regression
Pouysségur, J., Dayan, F., & Mazure, N. M. (2006) · Nature · doi:10.1038/nature04871 · Cited by 1,676
LNA-mediated microRNA silencing in non-human primates
Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H. F., Berger, U., et al. (2008) · Nature · doi:10.1038/nature06783 · Cited by 1,589
(2000) · PubMed · Cited by 1,445
Tian, H., McKnight, S. L., & Russell, D. W. (1997) · Genes & Development · doi:10.1101/gad.11.1.72 · Cited by 1,351
Hypoxia-Inducible Factors, Stem Cells, and Cancer
Keith, B., & Simon, M. C. (2007) · Cell · doi:10.1016/j.cell.2007.04.019 · Cited by 1,179
Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response
Dewhirst, M. W., Cao, Y., & Moeller, B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2397 · Cited by 1,022
Role of VHL Gene Mutation in Human Cancer
Kim, W. Y., & Kaelin, W. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.061 · Cited by 955
Novel advancements in the management of hepatocellular carcinoma in 2008
Llovet, J. M., & Bruix, J. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.01.022 · Cited by 811
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
Kondo, K., Klco, J., Nakamura, E., Lechpammer, M., & Kaelin, W. G. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00043-0 · Cited by 761
LNA (Locked Nucleic Acid): High-Affinity Targeting of Complementary RNA and DNA
Vester, B., & Wengel, J. (2004) · Biochemistry · doi:10.1021/bi0485732 · Cited by 727
Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression
Makino, Y., Cao, R., Svensson, K., Bertilsson, G., Asman, M., Tanaka, H., Cao, Y., Berkenstam, A., & Poellinger, L. (2001) · Nature · doi:10.1038/35107085 · Cited by 705
Chi, J., Wang, Z., Nuyten, D. S. A., Rodriguez, E. H., Schaner, M. E., Salim, A., Wang, Y., Kristensen, G. B., Helland, Å., Børresen‐Dale, A., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030047 · Cited by 625
Tang, N., Wang, L., Esko, J. D., Giordano, F. J., Huang, Y., Gerber, H., Ferrara, N., & Johnson, R. S. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.026 · Cited by 549
Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway
Kung, A. L., Zabludoff, S. D., France, D. S., Freedman, S. J., Tanner, E. A., Vieira, A., Cornell-Kennon, S., Lee, J., Wang, B., Wang, J., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.009 · Cited by 480
Maranchie, J. K., Vasselli, J. R., Riss, J., Bonifacino, J. S., Linehan, W. M., & Klausner, R. D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00044-2 · Cited by 442
Gleave, M. E., & Monia, B. P. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1631 · Cited by 384
PML inhibits HIF-1α translation and neoangiogenesis through repression of mTOR
Bernardi, R., Guernah, I., Jin, D. K., Grisendi, S., Alimonti, A., Teruya‐Feldstein, J., Cordon‐Cardo, C., Simon, M. C., Rafii, S., & Pandolfi, P. P. (2006) · Nature · doi:10.1038/nature05029 · Cited by 379
Evaluation of HIF-1 inhibitors as anticancer agents
Semenza, G. L. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.08.006 · Cited by 363
Baysal, B. E., Willett-Brozick, J. E., Lawrence, E. C., Drovdlic, C. M., Savul, S. A., McLeod, D. R., Yee, H. A., Brackmann, D. E., Slattery, W. H., Myers, E. N., et al. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.3.178 · Cited by 336
Koh, M. Y., Spivak-Kroizman, T., Venturini, S., Welsh, S., Williams, R. R., Kirkpatrick, D. L., & Powis, G. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0463 · Cited by 309
HIF-1 and HIF-2: working alone or together in hypoxia?
Ratcliffe, P. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31750 · Cited by 293
Dean, N. M., McKay, R. A., Condon, T. P., & Bennett, C. F. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)34023-1 · Cited by 291
(2010) · CRC Press eBooks · doi:10.1201/9781420002546 · Cited by 270
Calvani, M., Rapisarda, A., Uranchimeg, B., Shoemaker, R. H., & Melillo, G. (2005) · Blood · doi:10.1182/blood-2005-09-3541 · Cited by 233
Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma
Wu, X., Xie, G. R., & Chen, D. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.04997.x · Cited by 213
Knocking down Disease with siRNAs
Dykxhoorn, D. M., & Lieberman, J. (2006) · Cell · doi:10.1016/j.cell.2006.07.007 · Cited by 201
Hypoxia-Inducible Factor 1α in Clear Cell Renal Cell Carcinoma
Klatte, T., Seligson, D. B., Riggs, S. B., Leppert, J. T., Berkman, M. K., Kleid, M. D., Yu, H., Kabbinavar, F. F., Pantuck, A. J., & Belldegrun, A. S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0411 · Cited by 187
Pollard, P. J., Spencer‐Dene, B., Shukla, D., Howarth, K. M., Nye, E. L., El-Bahrawy, M. A., Deheragoda, M. G., Kolatsi‐Joannou, M., McDonald, S. A. C., Martin, A., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.02.005 · Cited by 182
Inhibiting Hypoxia-Inducible Factor 1 for Cancer Therapy
Melillo, G. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0235 · Cited by 168
Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues.
Butler, M., Stecker, K., & Bennett, C. F. (1997) · PubMed · Cited by 151
Kietzmann, T., Cornesse, Y., Brechtel-Curth, K., MODARESSI, S., & Jungermann, K. A. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3540531 · Cited by 141
Graham, M. J., Crooke, S. T., Monteith, D., Cooper, S. R., Lemonidis, K. M., Stecker, K., Martin, M. J., & Crooke, R. M. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37605-0 · Cited by 140
Renal Cell Carcinoma: New Developments in Molecular Biology and Potential for Targeted Therapies
Costa, L. J., & Drabkin, H. A. (2007) · The Oncologist · doi:10.1634/theoncologist.12-12-1404 · Cited by 126
Development of novel therapeutic strategies that target HIF-1
Semenza, G. L. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.2.267 · Cited by 120
Henke, E., Perk, J., Vider, J., de Candia, P., Chin, Y., Solit, D. B., Ponomarev, V., Cartegni, L., Manova, K., Rosen, N. X., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1366 · Cited by 117
A chemical genomics screen highlights the essential role of mitochondria in HIF-1 regulation
Lin, X., David, C. A., Donnelly, J. B., Michaelides, M. R., Chandel, N. S., Huang, X., Warrior, U., Weinberg, F. D., Tormos, K. V., Fesik, S. W., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706585104 · Cited by 115
Venetsanakos, E., Mirza, A. M., Fanton, C. P., Romanov, S. R., Tlsty, T. D., & McMahon, M. (2002) · Experimental Cell Research · doi:10.1006/excr.2001.5424 · Cited by 109
Li, L., Li, X., Staver, M. J., Shoemaker, A. R., Semizarov, D., Fesik, S. W., & Shen, Y. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4426 · Cited by 109
Kietzmann, T., Cornesse, Y., BRECHTEL, K., et al. (2001) · Biochemical Journal · doi:10.1042/bj3540531 · Cited by 106
Liposomal Formulations for Nucleic Acid Delivery
MacLachlan, I. (2007) · CRC Press eBooks · doi:10.1201/9780849387951-16 · Cited by 57
Fumarate Hydratase Deficiency and Cancer: Activation of Hypoxia Signaling?
Ratcliffe, P. J. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.03.015 · Cited by 50
Størling, Z. M., & Koch, T. (2008) · Wiley Encyclopedia of Chemical Biology · doi:10.1002/9780470048672.wecb516 · Cited by 39
Liposomal Formulations for Nucleic Acid Delivery
MacLachlan, I. (2007) · CRC Press eBooks · doi:10.1201/9780849387951.ch9 · Cited by 31
Koch, T., & Ørum, H. (2007) · CRC Press eBooks · doi:10.1201/9780849387951.ch19 · Cited by 8
Self-citationHypoxia-Inducible Factor 1A in Clear Cell Renal Cell Carcinoma
Klatte, T., Seligson, D. B., Riggs, S. B., Berkman, M. K., Kleid, M. D., Kabbinavar, F. F., Pantuck, A. J., & Belldegrun, A. S. (2007) · Cited by 7
Cited by
Sorted by citations
Hypoxia-inducible factors and the response to hypoxic stress
Majmundar, A. J., Wong, W. J., & Simon, M. C. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.022 · Cited by 2,380
The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy
Muz, B., de la Puente, P., Azab, F., & Azab, A. K. (2015) · Hypoxia · doi:10.2147/hp.s93413 · Cited by 2,066
“gave effective results and a safe toxicity in a Phase I clinical trial in metastatic, advanced solid malignancy.(85) Targeting”
BackgroundHIF-1α pathway: role, regulation and intervention for cancer therapy
Masoud, G. N., & Li, W. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.05.007 · Cited by 1,871
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
Semenza, G. L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.01.005 · Cited by 1,514
Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer
Wigerup, C., Påhlman, S., & Bexell, D. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.009 · Cited by 687
“…Glyceollins AKT/mTOR, Hsp90 Lee et al., 2015 Topotecan, PEG-SN38 Topoisomerase 1 Rapisarda et al., 2004, Pastorino et al., 2010 EZN-2968 HIF-1α mRNA Greenberger et al., 2008 2ME2, ENMD-1198 Microtubules Mabjeesh et al., 2003; LaVallee et al., 2008 Geldanamycin and analogs Hsp90 Isaacs et al.,…”
Background
Metadata
- Authors
- Greenberger, L. M., Horak, I. D., Filpula, D., Sapra, P., Westergaard, M., Frydenlund, H. F., Albæk, C., Schrøder, H., & Ørum, H.
- Affiliations
- Enzon Pharmaceuticals (United States) (US)
- 2Santaris Pharma A/S, Copenhagen, Denmark
- Venue
- Molecular Cancer Therapeutics
- Published
- 2008-11-01
- Volume
- 7
- Issue
- 11
- Pages
- 3598-3608
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2158916045
- Cited by
- 245
- References
- 49
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 12 · 2023: 13 · 2022: 13 · 2021: 19 · 2020: 11 · 2019: 10 · 2018: 8 · 2017: 7 · 2016: 10 · 2015: 12 · 2014: 22 · 2013: 22 · 2012: 25
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Molecular Cancer Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- HIF-1α, HIF-1, RNA interference, locked nucleic acid, prostate cancer, glioblastoma, tumor growth inhibition, angiogenesis, vascular endothelial growth factor, hypoxia
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Liver, Mice, Inbred C57BL, Oligonucleotides, RNA, Messenger, Transcription, Genetic, Transfection, Down-Regulation, Models, Animal, Cell Line, Tumor, Mice, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
